194 related articles for article (PubMed ID: 30504321)
21. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Nazha A; Sekeres MA; Gore SD; Zeidan AM
Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
[TBL] [Abstract][Full Text] [Related]
22. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
23. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
[TBL] [Abstract][Full Text] [Related]
24. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
Zeidan AM; Al Ali N; Barnard J; Padron E; Lancet JE; Sekeres MA; Steensma DP; DeZern A; Roboz G; Jabbour E; Garcia-Manero G; List A; Komrokji R
Leukemia; 2017 Jun; 31(6):1391-1397. PubMed ID: 28111463
[TBL] [Abstract][Full Text] [Related]
25. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.
Jabbour E; Takahashi K; Wang X; Cornelison AM; Abruzzo L; Kadia T; Borthakur G; Estrov Z; O'Brien S; Mallo M; Wierda W; Pierce S; Wei Y; Sole F; Chen R; Kantarjian H; Garcia-Manero G
Am J Hematol; 2013 Oct; 88(10):831-7. PubMed ID: 23760779
[TBL] [Abstract][Full Text] [Related]
26. The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features.
Greenberg PL
J Natl Compr Canc Netw; 2013 Jul; 11(7):877-84; quiz 885. PubMed ID: 23847221
[TBL] [Abstract][Full Text] [Related]
27. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.
Zhang L; McGraw KL; Sallman DA; List AF
Leuk Lymphoma; 2017 Aug; 58(8):1777-1790. PubMed ID: 27967292
[TBL] [Abstract][Full Text] [Related]
28. Clinical and genetic predictors of prognosis in myelodysplastic syndromes.
Bejar R
Haematologica; 2014 Jun; 99(6):956-64. PubMed ID: 24881041
[TBL] [Abstract][Full Text] [Related]
29. Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies.
Oosterveld M; Suciu S; Muus P; Germing U; Delforge M; Belhabri A; Aul C; Selleslag D; Ferrant A; Marie JP; Amadori S; Jehn U; Mandelli F; Hess U; Hellström-Lindberg E; Cakmak-Wollgast S; Vignetti M; Labar B; Willemze R; de Witte T
Ann Hematol; 2015 Jan; 94(1):23-34. PubMed ID: 25096636
[TBL] [Abstract][Full Text] [Related]
30. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
31. Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes.
Hasserjian RP; Buckstein R; Patnaik MM
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():328-350. PubMed ID: 34010050
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M
Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406
[TBL] [Abstract][Full Text] [Related]
33. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
[TBL] [Abstract][Full Text] [Related]
34. Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database.
Shukron O; Vainstein V; Kündgen A; Germing U; Agur Z
Am J Hematol; 2012 Sep; 87(9):853-60. PubMed ID: 22674538
[TBL] [Abstract][Full Text] [Related]
35. Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis.
Alvarez-Larrán A; López-Guerra M; Rozman M; Correa JG; Hernández-Boluda JC; Tormo M; Martínez D; Martín I; Colomer D; Esteve J; Cervantes F
Ann Hematol; 2019 Oct; 98(10):2319-2328. PubMed ID: 31396671
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors in the myelodysplastic syndromes.
Tricot GJ
Leuk Res; 1992; 16(1):109-15. PubMed ID: 1732663
[TBL] [Abstract][Full Text] [Related]
37. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms.
Merz AMA; Platzbecker U
Exp Hematol; 2024 Feb; 130():104130. PubMed ID: 38036096
[TBL] [Abstract][Full Text] [Related]
38. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
39. The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?
Otrock ZK; Tiu RV; Maciejewski JP; Sekeres MA
Expert Rev Hematol; 2013 Feb; 6(1):59-68. PubMed ID: 23373781
[TBL] [Abstract][Full Text] [Related]
40. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
